Luckin Coffee surpassed Starbucks in China sales, marking a competitive shift. Simultaneously, NAVER 1784 has deployed 100 robots to enhance service efficiency for Starbucks and other tasks.
Challenges from Cotti and Luckin Coffee
Luckin Coffee outpaced Starbucks in annual sales in China for the first time. This marked a substantial challenge for the Seattle-based company, underscoring the need for strategic responses.
According to WION, contrary to the perception of a potential price war, Starbucks has strategically shifted its approach. Industry experts and Chinese customers have noticed increased discount coupons distributed through various channels such as mini-programs, Douyin livestreams, and third-party delivery services.
These coupons, often offering 30% off or two-for-one deals, indicate a shift towards sales-driven strategies rather than direct price reductions.
In January, Belinda Wong, CEO of Starbucks China, said, "We are not interested in entering the price war." Founder Howard Schultz said the same thing in March when he went to Shanghai. He stressed how important it is for the company to grow in a way that makes money over the long run.
Discount Strategies as Starbucks' Response to Competitors
Although the extent of Starbucks' increased discounting remains undisclosed, the company had not previously employed such strategies.
Jason Yu, managing director of Kantar Worldpanel for Greater China, asserts that Starbucks is compelled to engage in price competition in a market where "the new normal" is low-cost competition. He observes that promotional offers must be strengthened to maintain market share, and social media activity must increase.
Price pressure is exacerbated by rivals, including Cotti, a chain established by former Luckin Chairman Charles Lu, and Luckin Coffee, which consistently offers espresso at significantly reduced prices. Luckin's rapid expansion, which has resulted in more than 18,590 locations by 2025, in contrast to Starbucks' intended 9,000, presents an additional obstacle for the latter.
NAVER 1784's Robot Deployment
Naver 1784 tower is the world's largest robotics testbed and the headquarters of the South Korean technology firm Naver. Interesting Engineering shares that Naver's autonomous service robot, Rookie, serves as a bearer at Starbucks and other services in the 36-storey building on the southern outskirts of Seoul.
On a regular day, approximately 100 Rookie service bots move around all floors of NAVER 1784, delivering packages, coffee, and lunch boxes. Rookie is a self-driving, brainless, cloud-based robot, a technology being promoted by Naver for its range of service bots.
"It is amazing that so many robots are providing services non-stop in such a huge space. In 1784, daily service becomes daily testing, and each day's issues become the next day's updates," a post on the firm's website stated.
Photo: Zeq Qayong/Unsplash


GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 



